Highlights Newsletter 2

This newsletter presents you the following key sessions:

1. PODCAST of dr. Robin Cornelissen about efficacy and safety of poziotinib in treatment-naïve NSCLC
    harboring HER2 exon 20 mutations

2. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab for early-stage
    triple-negative breast cancer

3. Nivolumab plus chemotherapy as standard first-line treatment option for patients with advanced gastric
    and oesophageal cancers

4. EGFR TKI therapy for NSCLC patients with uncommon EGFR mutations: results of a real-world study
    (UpSwinG)

5. Adding abiraterone to androgen deprivation therapy plus docetaxel improves outcomes in men with
    metastatic castration-sensitive prostate cancer